Evidence map›Paper›PMID 41964100›Full record

ArticleActa neuropathologica communications2026

Timing of microglial ablation determines protection from tau-mediated neurodegeneration and cognitive decline.

Paula Trigo-Alonso, Enrique Luengo, Cristina Fernández-Mendivíl, Lucía Viqueira, Nuria García-Magro, Eric Del Sastre, Juan Antonio Bernal, Pilar Negredo, Manuela G López

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paula Trigo-Alonso *Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain.
Enrique Luengo *Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain.
Cristina Fernández-MendivílDepartment of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain.
Lucía ViqueiraDepartment of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain.
Nuria García-MagroDepartmento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Eric Del SastreDepartment of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain.
Juan Antonio BernalMyocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Pilar NegredoDepartmento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Manuela G LópezDepartment of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029, Madrid, Spain. manuela.garcia@uam.es.

Funding

Comunidad de Madrid P2022/BMD-7230Ministerio de Ciencia, innovacion y universidades FPU16/03239Ministerio de Ciencia, innovacion y universidades FPU18/00630Ministerio de Ciencia, innovacion y universidades FPU20/03747Ministerio de Ciencia, innovacion y universidades PDC2022-133809-I00 and PID2021-125986OBMinisterio de Ciencia, innovacion y universidades PID2021-125039NB-I00Ministerio de Ciencia, innovacion y universidades PID2023-151105OB-I00
6 · The paper itself

Abstract

Tauopathies comprise a diverse group of neurodegenerative diseases characterized by intracellular aggregation of the microtubule-associated protein tau, neuroinflammation, and neuronal loss. Since tau pathology shows the strongest correlation with cognitive decline in Alzheimer's disease, understanding how microglia contribute to tau-mediated neurodegeneration remains a critical question. Here, we validated a tauopathy mouse model that progressively recapitulates key pathological features of tauopathy. Bilateral hippocampal injection of AAV-hTau

Indexed as

Cognitive DysfunctionMicrogliaTauopathiestau ProteinsAnimalsDisease Models, AnimalHippocampusHumansMaleMiceMice, TransgenicOrganic ChemicalsReceptors, Granulocyte-Macrophage Colony-Stimulating FactorTime FactorsCsf1r protein, mouseOrganic ChemicalsPLX5622Receptors, Granulocyte-Macrophage Colony-Stimulating Factortau ProteinsCognitive declineMicrogliaNeurodegenerationPLX5622Tauopathy

Identifiers

PMID41964100
PMCPMC13495438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.